Praxis Precision Medicines (NASDAQ:PRAX) Releases Quarterly Earnings Results, Beats Expectations By $0.38 EPS

Praxis Precision Medicines (NASDAQ:PRAX) announced its earnings results on Thursday. The company reported ($3.20) earnings per share for the quarter, beating the consensus estimate of ($3.58) by $0.38, FiscalAI reports.

Here are the key takeaways from Praxis Precision Medicines’ conference call:

• NDAs accepted for ulixacaltamide and relutrigine with PDUFA dates set (ulixacaltamide: Jan 29; relutrigine: Sep 27), and the company is scaling its commercial organization, distribution and payer/access efforts ahead of potential U.S. launches.
• Enrollment for the EMERALD study is complete and top-line results are expected in Q4; a positive readout could support a supplemental NDA to expand relutrigine into the broader DEE population (~200,000 U.S. patients), materially increasing commercial potential.
• EMBRAVE Part A data for the Solidus ASO elsunersen showed a 77% placebo‑adjusted reduction in monthly seizures and signs of disease‑modifying benefit in SCN2A early‑onset DEE with a generally favorable tolerability profile.
• The vormatrigine program has near‑term catalysts — POWER1 readout later this quarter and ongoing POWER2/POWER3 studies — and management reports encouraging blinded safety data and expectation of meaningful efficacy across flexible 20/30/40 mg dosing.
• Q1 financials showed operating expenses of ~$106M and $86M of cash used (up versus prior year) but a strengthened cash balance of ~$1.4B after a January follow‑on offering, which management says funds operations into 2028.

Praxis Precision Medicines Stock Down 1.0%

Shares of PRAX stock opened at $330.02 on Friday. The business has a 50 day moving average of $317.78 and a two-hundred day moving average of $277.56. Praxis Precision Medicines has a 52 week low of $35.21 and a 52 week high of $356.00. The company has a market cap of $9.20 billion, a P/E ratio of -24.68 and a beta of 2.76.

Hedge Funds Weigh In On Praxis Precision Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Los Angeles Capital Management LLC acquired a new position in Praxis Precision Medicines in the fourth quarter valued at approximately $163,000. Commonwealth Equity Services LLC acquired a new position in Praxis Precision Medicines in the fourth quarter valued at approximately $220,000. O Shaughnessy Asset Management LLC acquired a new position in Praxis Precision Medicines in the fourth quarter valued at approximately $226,000. Amundi acquired a new position in Praxis Precision Medicines in the fourth quarter valued at approximately $233,000. Finally, Ieq Capital LLC acquired a new position in Praxis Precision Medicines in the fourth quarter valued at approximately $240,000. 67.84% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Praxis Precision Medicines

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: The company reported first-quarter 2026 results with a smaller-than-expected loss, as EPS of ($3.20) beat estimates of ($3.58), which can help reassure investors ahead of future commercialization. Praxis earnings report
• Positive Sentiment: Praxis said the FDA accepted NDA filings for ulixacaltamide in essential tremor and relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies, giving the pipeline clearer regulatory timelines and potential catalysts in 2026-2027. Corporate update and Q1 2026 results
• Neutral Sentiment: BTIG reiterated a Buy rating and raised its price target sharply to $843, signaling strong long-term optimism even after the stock’s recent run-up. BTIG research update
• Negative Sentiment: Wedbush raised its target to $166 but kept an Underperform rating, highlighting meaningful downside risk versus the current share price and creating a conflicting message for investors. Wedbush rating update
• Neutral Sentiment: A Globe and Mail article noted analysts are bullish on Praxis alongside other healthcare names, adding to the broader positive attention on the stock. Analysts bullish on PRAX

Analyst Ratings Changes

PRAX has been the subject of several recent analyst reports. Piper Sandler restated an “overweight” rating and set a $1,200.00 target price (up from $450.00) on shares of Praxis Precision Medicines in a research note on Wednesday, January 28th. HC Wainwright restated a “buy” rating and set a $1,245.00 target price on shares of Praxis Precision Medicines in a research note on Tuesday, April 7th. Jefferies Financial Group restated a “buy” rating on shares of Praxis Precision Medicines in a research note on Thursday. Raymond James Financial started coverage on Praxis Precision Medicines in a research note on Friday, April 10th. They set a “strong-buy” rating and a $815.00 target price for the company. Finally, Wolfe Research started coverage on shares of Praxis Precision Medicines in a research report on Monday, February 23rd. They set an “outperform” rating and a $500.00 price target on the stock. Five research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Praxis Precision Medicines currently has an average rating of “Buy” and a consensus price target of $591.83.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.